Overview
Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm.
Indication
For use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits.
Associated Conditions
- Delayed Ischemic Neurological Deficit
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/07/02 | Not Applicable | Recruiting | |||
2025/05/31 | Not Applicable | Recruiting | Hans-Peter Landolt | ||
2025/03/28 | Phase 2 | Not yet recruiting | |||
2023/08/16 | Phase 3 | Active, not recruiting | |||
2022/06/14 | Phase 1 | Completed | |||
2021/11/23 | Phase 2 | Completed | |||
2021/06/28 | N/A | UNKNOWN | Second Affiliated Hospital, School of Medicine, Zhejiang University | ||
2021/06/11 | Early Phase 1 | Recruiting | |||
2021/03/17 | Phase 2 | Recruiting | |||
2020/12/02 | N/A | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Azurity Pharmaceuticals, Inc. | 24338-230 | ORAL | 30 mg in 5 mL | 5/31/2022 | |
| Azurity Pharmaceuticals, Inc. | 24338-260 | ORAL | 60 mg in 10 mL | 5/31/2022 | |
| McKesson Corporation dba SKY Packaging | 63739-797 | ORAL | 30 mg in 1 1 | 12/13/2023 | |
| Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 23155-512 | ORAL | 30 mg in 1 1 | 9/8/2022 | |
| BIONPHARMA INC. | 69452-209 | ORAL | 30 mg in 1 1 | 12/27/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| NIMOTOP FOR INFUSION 0.02% | SIN06931P | INJECTION | 0.02% | 4/13/1992 | |
| NIMOTOP TABLET 30 mg | SIN09111P | TABLET, FILM COATED | 30 mg | 12/28/1996 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Nimodipine Oral Solution | 国药准字H20234476 | 化学药品 | 口服溶液剂 | 11/14/2023 | |
| Nimodipine Oral Solution | 国药准字H20254009 | 化学药品 | 口服溶液剂 | 4/30/2025 | |
| Nimodipine Oral Solution | 国药准字H20254010 | 化学药品 | 口服溶液剂 | 4/30/2025 | |
| Nimodipine Oral Solution | 国药准字H20253866 | 化学药品 | 口服溶液剂 | 4/15/2025 | |
| Nimodipine Oral Solution | 国药准字H20253289 | 化学药品 | 口服溶液剂 | 1/24/2025 | |
| Nimodipine Oral Solution | 国药准字H20243913 | 化学药品 | 口服溶液剂 | 6/4/2024 | |
| Nimodipine Oral Solution | 国药准字H20223014 | 化学药品 | 口服溶液剂 | 1/18/2022 | |
| Nimodipine Oral Solution | 国药准字H20244285 | 化学药品 | 口服溶液剂 | 6/28/2024 | |
| Nimodipine Oral Solution | 国药准字H20244290 | 化学药品 | 口服溶液剂 | 6/28/2024 | |
| Nimodipine Dispersible Tablets | 国药准字H20000235 | 化学药品 | 片剂(分散) | 7/2/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| NIMOTOP nimodipine 30 mg tablets blister pack | 43100 | Medicine | A | 6/9/1993 | |
| NIMODIPINE JUNO nimodipine 10 mg/50 mL concentrated intravenous infusion solution vial | 335255 | Medicine | A | 11/8/2021 | |
| NIMOTOP 10mg/50mL injection vial | 43101 | Medicine | A | 6/9/1993 |
Help Us Improve
Your feedback helps us provide better drug information and insights.